About Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
KTTA Key Statistics
| Current Price | $0.80 | Market Cap | $18 million |
|---|---|---|---|
| Daily Change | +0.82% | Volume | 29K |
| 52-Week High | $3.79 | 52-Week Low | $0.28 |
| Sector | Healthcare | Industry | Biotechnology |
KTTA Price Performance
Pasithea Therapeutics Corp. stock has returned -3.66% over the past day, -5.95% over the past week, +12.86% over the past month, and -10.23% over the past three months. The stock trades between a 52-week low of $0.28 and a high of $3.79.